ArticleAmerican heart journal2005
Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry.
Article in American heart journal, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01321255 (Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Effect of evidence-based therapy for secondary prevention of cardiovascular disease: Systematic review and meta-analysis.PloS one · 2019Pooled it
- Long-term impact of secondary preventive treatments in patients with stable angina.European journal of epidemiology · 2011Trial
- The Prevalence and Impact of Evidence-Based Medications on Cardiovascular and Cerebrovascular Outcomes in Patients with Acute Coronary Syndrome Post-Revascularization in Oman.Pharmacy (Basel, Switzerland) · 2023Article
- Evaluation of medication compliance for secondary prevention of acute coronary syndrome.Proceedings (Baylor University. Medical Center) · 2017Article
- Optimal medical therapy for secondary prevention after an acute coronary syndrome: 18-month follow-up results at a tertiary teaching hospital in South Korea.Therapeutics and clinical risk management · 2016Article
- Article
- Long-term survival in patients with different combinations of evidence-based medications after incident acute myocardial infarction: results from the MONICA/KORA Myocardial Infarction Registry.Clinical research in cardiology : official journal of the German Cardiac Society · 2014Article
- Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France.European journal of clinical pharmacology · 2014Article
- Evaluation of proper prescribing of cardiac medications at hospital discharge for patients with acute coronary syndromes (ACS) in two Lebanese hospitals.SpringerPlus · 2014Article
- Improving health outcomes: innovation, coverage, quality and adherence.Israel journal of health policy research · 2012Article
- Prediction of persistence of combined evidence-based cardiovascular medications in patients with acute coronary syndrome after hospital discharge using neural networks.Medical & biological engineering & computing · 2011Article
- Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population.Nature clinical practice. Cardiovascular medicine · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral classes of medications improve survival in patients with coronary artery disease. Whether these medications, as used in the real world, have additive efficacy remains speculative.
objectivesTo assess whether patients discharged on combined secondary prevention medications after acute myocardial infarction (AMI) have improved 1-year survival, compared with the action of any single class of medications. DESIGN AND
settingNationwide registry of consecutive patients admitted to intensive care units for AMI in November 2000 in France. Multivariate Cox regression analysis, including a propensity score for the prescription of combined therapy, was used.
resultsOf the 2119 patients discharged alive, 1095 (52%) were prescribed a combination of antiplatelet agents, beta-blockers, and statins (triple therapy), of whom 567 (27%) also received angiotensin-converting enzyme inhibitors (quadruple therapy) and 528 (25%) did not. One-year survival was 97% in patients receiving triple combination therapy versus 88% in those who received either none, 1, or 2 of these medications (P < .0001). After multivariate adjustment including the propensity score, the hazard ratio for 1-year mortality in patients with triple combination therapy was 0.52 (95% CI 0.33-0.81). In patients with ejection fraction < or = 35%, beta-blockers and angiotensin-converting enzyme inhibitors were independent predictors of survival, and combination therapy had no additional prognostic value.
conclusionsCompared with the prescription of any single class of secondary prevention medications, combination therapy offers additional protection in patients with AMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.